Novo Nordisk AS’s investigational GLP-1 agonist semaglutide demonstrated a significant reduction in major adverse cardiovascular events in the SUSTAIN-6 cardiovascular outcomes trial, which will strengthen its new drug application for the therapy and supplement future negotiations with pricing regulators.
The full data from the SUSTAIN-6 non-inferiority study were presented on Sept. 16 to rapturous applause at the European Association...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?